Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors

PURPOSE: To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide. METHODS: Patients with advanced, solid...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Kelly K., Sarantopoulos, John, Northfelt, Donald W., Weiss, Glen J., Barnhart, Kerry M., Whisnant, John K., Leuschner, Carola, Alila, Hector, Borad, Mitesh J., Ramanathan, Ramesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000412/
https://www.ncbi.nlm.nih.gov/pubmed/24610297
http://dx.doi.org/10.1007/s00280-014-2424-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000412/
https://www.ncbi.nlm.nih.gov/pubmed/24610297
http://dx.doi.org/10.1007/s00280-014-2424-x

Ejemplares similares